KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non Operating Income (2018 - 2025)

Acadia Pharmaceuticals (ACAD) has 8 years of Other Non Operating Income data on record, last reported at $596000.0 in Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 3.65% year-over-year to $596000.0; the TTM value through Dec 2025 reached $2.4 million, up 30.06%, while the annual FY2025 figure was $2.4 million, 30.06% up from the prior year.
  • Other Non Operating Income reached $596000.0 in Q4 2025 per ACAD's latest filing, up from $592000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $4.8 million in Q1 2023 and bottomed at -$1.2 million in Q2 2023.
  • Average Other Non Operating Income over 5 years is $798631.6, with a median of $576000.0 recorded in 2024.
  • Peak YoY movement for Other Non Operating Income: crashed 206.2% in 2022, then soared 1325.0% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $1.6 million in 2021, then decreased by 4.93% to $1.5 million in 2022, then fell by 2.27% to $1.5 million in 2023, then plummeted by 61.87% to $575000.0 in 2024, then rose by 3.65% to $596000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $596000.0 in Q4 2025, $592000.0 in Q3 2025, and $595000.0 in Q2 2025.